Yoshinobu Koguchi

1 ta ish

Providence Portland Medical Center

1. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

   Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye +12

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.296875